19
Jul

A new tool helps remove the emotion around choosing the right approach for prostate cancer

How to Decide if Watchful Waiting is the Right Choice (PHILADELPHIA) – Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options: active surveillance, also called watchful waiting, in which …

12
Jul

Kennedy Health joins The Sidney Kimmel Cancer Network

Kennedy Health’s Cancer Center is the newest member of the Sidney Kimmel Cancer Network at Jefferson. As a cancer center network member, resources will be available to the Kennedy Cancer Center and its patients, creating local access to medical expertise, second opinions and advanced research. Learn more about the partnership. Effective July 1, Kennedy Health’s …

11
Jul

Immunotherapy for Melanoma Ignites a ‘Scientific Revolution and Promise of a Cure’

Learn more by reading a recent blog by Marlana Orloff, MD, Assistant Professor of Medical Oncology at Sidney Kimmel Medical College and researcher at Sidney Kimmel Cancer Center. “Success in melanoma has propelled the use of these drugs into many other cancers including lung, kidney, breast, pancreatic, leukemias, lymphomas, and brain, most of which remain …

29
Jun

Award of Doctor of Medical Science (Honoris Causa), University of Melbourne to Professor Richard Pestell

Dr. Pestell, was honored with the Award of Doctor of Medical Science (Honoris Causa) from the Melbourne University citing his “profound impact on the diagnosis and treatment of cancer and on the teaching, clinical, research organizations that share his determination”.  Dr. Pestell is currently one of the highest cited researcher in the world by Google …

27
Jun

Renée de Leeuw, PhD recevies 2016 Marjorie Katz Foundation–PCF Young Investigator Award

Prostate Cancer Foundation Announces 24 New Young Investigator Awards Class of 2016 Represents $5.4 Million Investment in the Future of Cancer CareSANTA MONICA, CA June 23, 2016 – The Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) Awards to pioneer increasingly precise treatments and faster cures for prostate cancer. Members …

24
Jun

Dr. Yang and Wang featured in Healio: MicroRNAs may predict risk for HCC in HBV

Circulating microRNAs may be used as noninvasive markers for predicting risk for developing hepatocellular carcinoma in patients with hepatitis B virus infection, according to recently published findings. “This research confirms previous work on microRNAs and liver cancer and goes further to show that these microRNAs may be able to predict the development of liver cancer …

23
Jun

Dr. Mathew Thakur Named SNMMI elected Fellow of Academy of Radiology Research Council

Nuclear Medicine and Molecular Imaging announced the creation of an SNMMI Fellowship recognizing distinguished service to SNMMI as well as exceptional achievement in the field of nuclear medicine and molecular imaging. The announcement was made during today’s Special Plenary Session at the society’s 2016 Annual Meeting, held June 11-15 in San Diego, Calif. “SNMMI Fellowship …

3
Jun

New Bladder Cancer Guidelines

Medscape Medical News recently spoke with Dr. Leonard Gomella, Chair of the Department of Urology and the Director of the Sidney Kimmel Cancer Center Network, about the new guidelines from American Urological Association (AUA) and the Society of Urologic Oncology (SUO) for managing bladder cancer*. The new guidelines affect both traditional and new therapies for …

2
Jun

Genomic Markers in Prostate Cancer

Dr. Leonard Gomella, Chair of the department of Urology and the Director of the Sidney Kimmel Cancer Center Network, was recently interviewed by Targeted Oncology about four major genomic markers used to guide treatment decisions in prostate cancer. These four genomic markers help clinicians decide between active treatment for patients with prostate cancer or active …

9
May

Radiation Oncology Podcast Series: Insights in Head and Neck Cancer: Treatment Options and Associated Toxicities.

Dr. Adam Dicker Chairman of the Department of Radiation Oncology conducts the latest Radiation Oncology podcast with Otolaryngologist Dr.  Adam Luginbuhl Key Discussions: Interest in Head & Neck Cancer His passion to reduce the toxicities of treatment His current collaborative research efforts How we resemble each other! Check out the Podcast (Click Here)

4
May

Jefferson’s Buddy Program Gives Patients with Cancer Somebody to Lean On

                                                                                                                                                                                                                                                                                                                        Joe Lavalle, a Sidney Kimmel Cancer Center at Jefferson Buddy Program volunteer. The Sidney Kimmel Cancer Center at Jefferson Buddy Program matches patients diagnosed with prostate, breast and other types of cancer with survivors who have experienced the same or similar diagnoses, treatments and uncertainties. Their “survivor buddies” are cancer survivors ahead of them …

3
May

Dr. Leonard Gomella: “Blue light” cystoscopy for detection and treatment of non-muscle invasive bladder cancer

Dr. Leonard Gomella, MD In patients with non-muscle invasive bladder cancer, fluorescence cystoscopy can improve the detection and ablation of bladder tumors. In this paper we describe the technique and practical aspects of hexaminolevulinate (HAL) fluorescence cystoscopy, also known as “blue light cystoscopy”. Check out Dr. Gomella’s  Blue Light Video (Click Here)

27
Apr

Jefferson Harnessing “Big Data” to Broaden Cancer Research

With the help of internal and external collaborations, researchers in our Computational Medicine Center (CMC) at the Sidney Kimmel Medical College here at TJU are characterizing and analyzing the molecular drivers of several cancers, which may lead to more powerful diagnostics and personalized treatments that better target cancer’s root causes. The use of precision medicine …

26
Apr

Researchers Find Pathway that Could Make Abandoned Pancreatic Cancer Drug Effective Against the Disease

Our scientists have found that blocking one molecular pathway could make pancreatic cancer susceptible to formerly ineffective therapies. “While there’s more work to be done to confirm the results in pre-clinical models and then humans, we are encouraged by these preliminary results,” said Jonathan Brody, PhD, a researcher at our Sidney Kimmel Cancer Center and Director …

23
Apr

Dr. Gomella featured in Targeted Oncology

Experts Discuss Treatment Sequencing Strategies in CRPC As the treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) continues to evolve, optimal strategies are becoming more apparent on how to best sequence the multitude of novel therapies that have been approved in the past decade. To gain insight into current best practices and strategies …

Page 1 of 22